Eleftherios P. Mamounas

Also affiliated with Florida Hospital Cancer Institute

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 12 papers. Top paper: “Neoadjuvant nab-paclitaxel in the treatment of breast cancer”.

Neoadjuvant nab-paclitaxel in the treatment of breast cancer

Breast Cancer Research and Treatment(2016)10.1007/s10549-016-3778-z

N/A

1.5DataRank · unranked

28 citations

Eleftherios P. Mamounas, Naoto T. Ueno

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

New England Journal of Medicine(2025)10.1056/nejmoa2414859

N/A

1.2DataRank · unranked

93 citations

Hanna Bandos, Julia White, Thomas B. Julian, Atif J. Khan, Simona F. Shaitelman +23 more

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.02344

N/A

0.646DataRank · unranked

17 citations

Jieling Miao, Lajos Pusztai, Matthew P. Goetz, Priya Rastogi, Patricia A. Ganz +17 more

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Breast Cancer Research and Treatment(2022)10.1007/s10549-021-06417-y

N/A

0.593DataRank · unranked

10 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad078

N/A

0DataRank · unranked

20 citations

Hanna Bandos, Priya Rastogi, Barry C. Lembersky, Jong‐Hyeon Jeong, Charles E. Geyer +11 more

Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.508

N/A

0DataRank · unranked

9 citations

Stewart Anderson, Kalliopi P. Siziopikou, Douglas W. Arthur, Thomas B. Julian, Rachel Rabinovitch +15 more

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps623

N/A

0DataRank · unranked

6 citations

Reena S. Cecchini, Eleanor Harris, Eleftherios P. Mamounas, Daniel G. Stover, Patricia A. Ganz +12 more

PRESCIENTai, an AI-based digital histopathological image signature for risk of late distant recurrence and extended endocrine therapy (EET) benefit in hormone receptor–positive breast cancer.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.1556

N/A

0DataRank · unranked

0 citations

Ming Chen, Tanner J. Freeman, Nicolas Stransky, Md. Samiur Rahman, Mark Miglarese +14 more

Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.524

N/A

0DataRank · unranked

12 citations

Adeline M. Deladisma, Erin M. Mobley, Shu Wang, Christopher G. Morris, Oluwadamilola T. Oladeru +11 more

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.501

N/A

0DataRank · unranked

22 citations

Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas +14 more

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.502

N/A

0DataRank · unranked

16 citations

Hanna Bandos, Peter C. Lucas, L. J. van ‘t Veer, Jia-Perng Jennifer Wei, Charles E. Geyer +15 more

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps613

N/A

0DataRank · unranked

31 citations

Stewart Anderson, Eleanor Harris, Eleftherios P. Mamounas, Daniel G. Stover, Patricia A. Ganz +11 more